Oxaceprol


Full Prescribing Info
Dosage/Direction for Use

Oral
Degenerative joint disorders
Adult: 200 mg tid. In severe cases, initial dose can be increased to 400 mg tid. Taken before a meal, unchewed.
Elderly: Dose reduction is recommended.

Oral

Inflammatory connective tissue diseases
Adult: 200 mg tid. In severe cases, initial dose can be increased to 400 mg tid. Taken before a meal, unchewed.
Elderly: Dose reduction is recommended.

Topical/Cutaneous

Superficial burns
Adult: 10% cream: Apply once a day.
Contraindications
Cream: infected skin lesions.
Special Precautions
Children, elderly, pregnancy, lactation.
Adverse Reactions
Gastric pain, nausea, diarrhoea, dizziness, headache and skin rashes.
Overdosage
Sedation, ptosis, piloerection.
Drug Interactions
Affects coagulation in patients under anticoagulative therapy with Vitamin K-antagonists. May decrease effects of anti-hypertensives. May affect toxicity of methotrexate and lithium.
Action
The exact mechanism of action of oxaceprol is not known. It affects connective tissue metabolism and has been used in dermatology, to promote wound healing, and in rheumatic disorders. Experimental models of arthritis showed that oxaceprol reduced leukocyte extravasation, as well as the adhesion of leukocytes to capillaries. In vitro studies have shown that oxaceprol stimulates the uptake of 3H-glucosamine and 3H-proline in chondrocytes and the incorporation of 3H-proline in the macromolecular structure of the matrix of cartilage; which would be responsible for the activity on regenerating tissue.
Absorption: 3.5 hr after oral admin.
Distribution: Permeates into the synovial fluid. Bio-availability after oral admin: approx 30%.
Excretion: Via urine (exclusively, unchanged and complete). Elimination half-life: 2.2 hr.
ATC Classification
D11AX09 - oxaceprol ; Belongs to the class of other dermatologicals.
M01AX24 - oxaceprol ; Belongs to the class of other non-steroidal antiinflammatory and antirheumatic products.
Disclaimer: This information is independently developed by CIMS based on oxaceprol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in